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Abstract
Background: The diagnosis of Human African Trypanosomiasis relies mainly on the Card Agglutination Test for
Trypanosomiasis (CATT). While this test is successful, it is acknowledged that there may be room for improvement. Our aim
was to develop a prototype lateral flow test based on the detection of antibodies to trypanosome antigens.
Methodology/Principal Findings: We took a non-biased approach to identify potential immunodiagnostic parasite protein
antigens. The IgG fractions from the sera from Trypanosoma brucei gambiense infected and control patients were isolated
using protein-G affinity chromatography and then immobilized on Sepharose beads. The IgG-beads were incubated with
detergent lysates of trypanosomes and those proteins that bound were identified by mass spectrometry-based proteomic
methods. This approach provided a list of twenty-four trypanosome proteins that selectively bound to the infection IgG
fraction and that might, therefore, be considered as immunodiagnostic antigens. We selected four antigens from this list
(ISG64, ISG65, ISG75 and GRESAG4) and performed protein expression trials in E. coli with twelve constructs. Seven soluble
recombinant protein products (three for ISG64, two for ISG65 and one each for ISG75 and GRESAG4) were obtained and
assessed for their immunodiagnostic potential by ELISA using individual and/or pooled patient sera. The ISG65 and ISG64
construct ELISAs performed well with respect to detecting T. b. gambiense infections, though less well for detecting T. b.
rhodesiense infections, and the best performing ISG65 construct was used to develop a prototype lateral flow diagnostic
device.
Conclusions/Significance: Using a panel of eighty randomized T. b. gambiense infection and control sera, the prototype
showed reasonable sensitivity (88%) and specificity (93%) using visual readout in detecting T. b. gambiense infections. These
results provide encouragement to further develop and optimize the lateral flow device for clinical use.
Citation: Sullivan L, Wall SJ, Carrington M, Ferguson MAJ (2013) Proteomic Selection of Immunodiagnostic Antigens for Human African Trypanosomiasis and
Generation of a Prototype Lateral Flow Immunodiagnostic Device. PLoS Negl Trop Dis 7(2): e2087. doi:10.1371/journal.pntd.0002087
Editor: Christian Tschudi, Yale School of Public Health, United States of America
Received November 16, 2012; Accepted January 17, 2013; Published February 28, 2013
Copyright:  2013 Sullivan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by an MRC PhD studentship to LS (http://www.mrc.ac.uk/index.htm), a Wellcome Trust Programme Grant to MAJF (085622)
and a Wellcome Trust project grant to MC (085256) (http://www.wellcome.ac.uk/). The mass spectrometry component was supported by Wellcome Trust Strategic
Awards (083481 and 100476). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: m.a.j.ferguson@dundee.ac.uk
Introduction
Human African Trypanosomiasis (HAT), also known as
Sleeping Sickness, is a disease caused by Trypanosoma brucei
gambiense and T. b. rhodesiense [1,2,3]. The parasites are transmitted
in sub-Saharan Africa by the bite from an infected tsetse fly. HAT
is of great public health significance, with epidemic outbreaks
recorded several times over the past century with, at times,
estimates of 300,000 or more infected individuals [4]. Today, the
recorded number of new cases has dropped below 10,000 per year,
yet HAT still continues to place a large burden on individuals and
communities in terms of disability-adjusted life years [5,6]. The
identification of infected individuals is crucial for therapeutic and
public health intervention. New tools could aid eradication of this
disease when used in coordination with other efforts [5,7,8].
Infection with T. b. gambiense or T. b. rhodesiense progresses
through two defined stages. The first stage is when trypanosomes
are limited to the blood and lymphatic systems. The second stage
occurs when the parasites invade the central nervous system [2].
The latter leads to neurological damage, sleep cycle disruption,
coma and death if the patient does not receive treatment [9,10,11].
The two stages are treated with different drugs, and those used for
the second stage have severe toxic side effects [12,13]. Staging of
the infection, to select the appropriate therapeutics and follow up,
is currently done by sampling the cerebral spinal fluid to search for
the presence of parasites and/or increased numbers of lympho-
cytes [14]. The view that human trypanosome infections are
invariably fatal if not treated has been challenged recently [15,16]
but, nevertheless, early diagnosis is extremely important both for
individual patient outcomes and for controlling epidemic spread
[17,18].
The identification of infected individuals relies on dedicated
screening teams that visit at-risk communities or patients seeking
medical examination [19]. HAT diagnosis in the field faces many
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difficulties; not least the logistical challenges for the screening
teams to attend communities in rural locations. In endemic areas,
civil disturbance usually increases the incidence of HAT and
decreases the frequency of screening [20,21,22]. Once the
screening teams are with the communities, they face further
challenges to recruit the entire local population into the HAT
screening programme, which can lead to under-reporting and
under-estimations of infection rates [23,24,25,26].
The current HAT screening regimen uses the Card Agglutina-
tion Test for Trypanosomiasis (CATT), a serological test that
detects whether antibodies from an individual are able to
aggregate a suspension of fixed and stained T. b. gambiense
trypanosomes [27], detecting primarily antibodies to the variant
surface glycoproteins (VSGs) on the fixed cells. If patients have a
positive CATT result, microscopic examination of their blood is
carried out to detect trypanosomes. If this is positive, a lumbar
puncture is performed to stage the infection. Over the years, the
CATT test has been optimised to improve sensitivity, specificity
and stability. Such modifications include dilution of the blood
samples, the use of multiple trypanosome clones expressing
different VSG variants and improvements in thermostability
[28,29,30,31]. Despite the usefulness and wide deployment of
the CATT test, it has several widely accepted limitations
[32,33,34,35]. These include varying degrees of sensitivity and
specificity, its inability to detect T. b. rhodesiense infections, the
requirement for trained screening personnel to use it and the
specialised manufacture which precludes production on a scale
necessary to saturate the market [26,36]. There have also been
other post-CATT test diagnostic enhancements. For example, the
concentration of trypanosomes from infected blood to improve
microscopic detection [37,38,39]. Further, the detection of
trypanosome DNA in blood by loop-mediated isothermal ampli-
fication of DNA (LAMP) [40] methods are under investigation and
are summarised in a recent review [41]. However, these diagnostic
methods require relatively sophisticated laboratory equipment. In
summary, there is well accepted case for developing an extremely
simple, low-cost diagnostic device with greater sensitivity and
specificity than current field tests [4].
Lateral flow devices are simple tests that can rapidly detect
nanogram amounts of antibodies or antigens in finger-prick blood
samples without the need for any ancillary equipment [42]. T. b.
gambiense infections are characterised by very low parasitemias,
often ,1000/ml, the equivalent of ,5 ng total trypanosome
protein/ml blood. Thus, using currently available technology, it is
not feasible to directly detect a trypanosome protein and a lateral
flow test that detects host antibodies is perhaps more likely to have
the required sensitivity and specificity. The manufacture of large
numbers of lateral flow devices requires milligram to gram
amounts of diagnostic antigen, therefore potential diagnostic
antigens for such devices should preferably derive from recombi-
nant or synthetic sources. Recently the Foundation for Innovative
New Diagnostics (FIND) has invested in developing new diagnostic
tests for human African Trypanosomiasis [43]. With a similar aim
in mind, we also set out to identify novel diagnostic antigens, and
to create a prototype lateral flow test device, but using a non-
biased (proteomics) approach to select potential biomarker
antigens. The results of this antigen selection and the performance
of a prototype lateral flow device are reported here.
Materials and Methods
Ethics statement
All human serum samples were collected with the informed
consent of the patients that they could be used anonymously for
diagnostic development. Rodents were used to propagate sufficient
T. brucei parasites to make the detergent lysates for immunoaffinity
chromatography and proteomics. The animal procedures were
carried out according the United Kingdom Animals (Scientific
Procedures) Act 1986 and according to specific protocols approved
by The University of Dundee Ethics Committee and as defined
and approved in the UK Home Office Project License PPL 60/
3836 held by MAJF.
Serum samples and storage
Two sets of human serum samples were used, the first was
kindly provided by Philippe Bu¨scher (Institute of Tropical
Medicine, Antwerp) and consisted of nine sera from T. b.
gambiense infected patients and nine from matched non-infected
patients. These samples underwent virus inactivation using a
procedure that retains antibody reactivity [44]. Briefly, 1% Tri(n-
butyl)phosphate (TnBP) and 1% Triton X-45 were added to
thawed serum samples and incubated at 31uC for 4 h. Sterile
castor oil was added, mixed and the samples were centrifuged
(38006 g, 30 min). The oil-extraction was repeated three times
and the virus-inactivated sera (lower phases) were aliquoted and
stored at 280uC. The second set of 145 patient sera (200 ml
aliquots) was obtained from the WHO Human African
Trypanosomiasis specimen bank [45]. Serum samples were
aliquoted and stored at either 280uC for long-term storage or
in 50% glycerol at 220uC when prepared for ELISA analysis.
Freeze-thawing was kept to a minimum; samples from P. Bu¨scher
and WHO were freeze-thawed three times and twice, respec-
tively, prior to use in ELISA tests.
IgG purification from serum
Following virus inactivation, 125 ml of sera from four infected
and four uninfected (control) patients were pooled. Each pool was
applied to a 1 ml protein G column (GE Healthcare) equilibrated
in phosphate buffered saline (PBS). The columns were washed
with 10 ml of PBS and the bound IgG antibodies were eluted with
50 mM sodium citrate pH 2.8, and collected in 1 ml fractions into
tubes containing 200 ml of 1 M Tris-HCl, buffer pH 8.5. Peak
fractions containing IgG were combined and dialysed for 16 h
against coupling buffer (0.1 M NaHCO3, 0.5 M NaCl, pH 8.3).
Author Summary
Human African Trypanosomiasis is caused by infection
with Trypanosoma brucei gambiense or T. b. rhodesiense.
Preliminary diagnosis of T. b. gambiense infection relies
mainly on a Card Agglutination Test for Trypanosomiasis
(CATT), which has acknowledged limitations. New ap-
proaches are needed, first to identify new diagnostic
antigens and, second, to find a more suitable platform for
field-based immunodiagnostic tests. We took an unbiased
approach to identify candidate diagnostic antigens by
asking which parasite proteins bind to the antibodies of
infected patients and not to the antibodies of uninfected
patients. From this list of twenty-four candidate antigens,
we selected four and from these we selected the one that
worked the best in conventional immunodiagnostic tests.
This antigen, ISG65, was used to make lateral flow devices,
where a small sample of patient serum is added to a pad
and thirty minutes later infection can be inferred by simple
optical read out. This simple prototype device works as
well as the CATT test and may be developed and
optimized for clinical use in the field.
A Diagnostic Device for African Trypanosomiasis
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Coupling of IgG to CNBr-activated Sepharose
CNBr-activated Sepharose (GE Healthcare) was hydrated in
1 mM HCl and then equilibrated in coupling buffer. Aliquots
(0.75 ml packed volume) were mixed with 7.2 mg of purified
infection IgG or purified control IgG in a final volume of 3 ml
coupling buffer for 16 h at 4uC. The coupling of IgG was
confirmed by measuring the absorbance of the supernatant at
280 nm before and after coupling. The Sepharose-IgG conjugates
were centrifuged at 5006 g (10 mins, 4uC) and the beads were
resuspended in 15 ml 1 M ethanoamine, pH 9, to block remain-
ing amine-reactive sites for 2 h at room temperature. Following
this, the IgG-Sepharose beads were washed with three cycles of
0.1 M Tris-HCl, pH 8.0, 0.5 M NaCl followed by 0.1 M sodium
acetate buffer, pH 6.0, 0.5 M NaCl and finally washed and stored
in PBS containing 0.05% NaN3.
Preparation T. b. brucei lysate
Six BalbC mice were injected with T. b. brucei Lister 427 variant
MITat 1.4 cells. After three days, infected mouse blood was
harvested with citrate anticoagulant, adjusted to 107 parasites per
ml with PBS and aliquots of 0.5 ml were injected into the
peritoneal cavity of 12 Wistar rats. The rat blood was harvested
after 3 days with citrate anticoagulant and centrifuged at 10006 g
for 10 min at 4uC. Plasma was removed and the buffy layer was
resuspended in separation buffer plus glucose (SB + glucose;
57 mM Na2HPO4, 3 mM KH2PO4, 44 mM NaCl, 10 g/l
glucose) and applied to a DE52 DEAE-cellulose (Whatman)
column that had been pre-equilibrated with SB + glucose. The
trypanosomes were washed through the column with SB + glucose,
counted, centrifuged (900 g, 15 min, 4uC), resuspended in 1 ml
PBS and then adjusted to 16109 parasites/ml in ice-cold lysis
Figure 1. Recombinant protein antigens used in this study. A generic representation of the ISGs is shown at the top and a representation of
GRESAG4 is shown at the bottom. All have cleavable N-terminal signal peptides and internal transmembrane domains, typical of type-1 membrane
proteins. The constructs prepared and expressed and the soluble proteins successfully purified, are indicated.
doi:10.1371/journal.pntd.0002087.g001
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buffer (50 mM Na2PO4, pH 7.2, 2% n-octyl b-D-glucopyranoside
(nOG) detergent, 1 mM PMSF, 1 mM TLCK, 1 mg/ml aprotinin,
1 mg/ml leupeptin and 16Roche protease cocktail minus EDTA).
The lysate was incubated for 30 min on ice and then centrifuged
at 100,000 g for 1 h at 4uC.
Immunoprecipitation
Aliquots of T. b. brucei lysate (1010 cell equivalents) were
incubated with 0.75 ml packed volume of each of the Sepharose-
IgG (infection and non-infection/control) gels, rotating for 3 h at
4uC. The gels were then packed into disposable 10 ml columns
and washed with 10 ml of 10 mM Na2PO4, pH 7.2, 200 mM
NaCl, 1% nOG, followed by 10 ml of 5 mM Na2PO4 pH 7.2, 1%
nOG. The trypanosome proteins were eluted 3 times with 750 ml
of 250 mM sodium citrate, pH 2.8, 1% nOG and the eluates were
pooled and neutralised with 1.5 M Tris-HCl, pH 9 and further
concentrated to 140 ml using a centrifugal concentrator (Millipore,
0.5 ml capacity with 3 kDa MW cut off membrane). To remove
eluted IgG, this fraction was mixed with 30 ml PBS-equilibrated
Protein G agarose beads (Pierce) and incubated for 10 min and
removed by centrifugation. The supernatant, containing the
trypanosome proteins, were then transferred to low binding
Eppendorf tubes and the proteins were precipitated by adding
1 ml ice-cold ethanol and incubation for 34 h at 220uC.
Proteomic protein identification
Following ethanol precipitation, the proteins eluted from the
infection IgG and control IgG gels were dissolved in SDS sample
buffer, reduced with DTT and run on a precast 4–12% BisTris
gradient SDS-PAGE gel (Invitrogen) using the MES running
system. The gel was stained with colloidal Coomassie blue and
equivalent regions of the infection and control lanes were cut out,
reduced and alkylated with iodoacetamide and digested in-gel with
trypsin. The tryptic peptides were analysed by LC-MS/MS on a
Thermo Orbotrap XL system and MASCOT software was used to
match peptides to the predicted trypanosome protein databases
(combined GeneDB and UniProt predicted protein sequences).
Selection of antigens and the cloning and sequencing of
antigen gene segments
Trypanosome proteins identified uniquely in the infection IgG
immunopurified fractions were considered for recombinant
expression. Within these, proteins with high MASCOT scores,
likely to be the most abundant, were prioritised for recombinant
expression and purification trials. These proteins included Gene
Related to Expression Site Associated Gene (GRESAG) 4,
Invariant Surface Glycoprotein (ISG) 75, ISG65 and ISG64.
The identified protein sequences were used to BLAST search the
T. b. brucei predicted protein database, revealing several related
protein sequences in each family. CLUSTALW2 alignments were
carried out in order to better understand sequence sub-groups
within those protein families. Representative gene segments from
each protein sub-group that contained the peptide sequences
Figure 2. Immuno-affinity chromatography and identification
of potential diagnostic antigens. (A) Schematic representation of
the preparation of IgG-Sepharose from T. b. gambiense infection and
non-infection (control) sera, the immune-affinity capture of trypano-
some antigens from a whole detergent lysate and their subsequent
elution and concentration by ethanol precipitation. (B) Colloidal
Comassie blue stained SDS-PAGE gel of the proteins eluted from
infection IgG-Sepharose (lane 1) and non-infection (control) IgG-
Sepharose (lane 2). The gel lanes were excised in 18 slices per lane,
as indicated between lanes 1 and 2, and analysed by LC-MS/MS after
reduction, S-alkylation and tryptic digestion. The positions of molecular
weight markers are indicated on the left.
doi:10.1371/journal.pntd.0002087.g002
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identified by mass spectrometry were amplified from EA-
TRO1125 genomic DNA (for ISG65-1, ISG65-2, ISG64-2,
ISG64-3 and ISG75-1) or from stain 427 genomic DNA (for
ISG64-1 and GRESAG4) by PCR using the primers described in
the Supporting Information (Table S1). In each case, the products
of three separate PCR reactions were cloned into a TOPO-TA
vector (pCR2.1) for sequencing (DNA Sequencing Service,
College of Life Sciences, University of Dundee).
Recombinant protein expression and purification
The amplified ISG gene segments were cloned into various pET
bacterial expression plasmids that provide a His-tag fused either to
the N-terminus or C-terminus of the protein, in some cases via a
TEV protease cleavage site, as indicated in (Figure 1). Multiple
constructs were designed for GRESAG4 encoding the predicted
full-length extracellular domain and several small globular
domains based on predictions from GLOBplot software [46]
(Figure 1). These constructs were amplified from genomic DNA
using the primers described in the Supporting Information (Table
S1), cloned into TOPO-TA vector pCR2.1 and verified by DNA
sequencing. The constructs were either cloned into the pET15b-
TEV vector, such that the proteins they encode are fused at the N-
terminus to a His tag, or into a pGEX-TEV vector such that the
protein is fused at its N-terminus to a glutathione S-transferase
(GST) sequence via a TEV cleavage site (Figure 1). The details of
protein expression in E. coli and subsequent purification are
described in the Supporting Information (Text S1).
Enzyme-linked immunosorbent assays (ELISA)
White (Costar) un-treated 96 well plates were coated at 50 ml/
well for 16 h at 4uC with 2 mg/ml recombinant protein diluted in
plating buffer (0.05 M NaHCO3, pH 9.6). Plating solution was
removed and wells were blocked with PBS containing 5% BSA,
200 ml/well for 3 h at 22uC or 16 h at 4uC. Plates were stored at
4uC and used within 24 h. Aliquots (50 ml) of serial serum dilutions
(see below) were transferred in triplicate by a liquid handling
device (Bio-Tek, Precision) to the ELISA plates and incubated for
1 h at room temperature, aspirated and 150 ml ELISA wash buffer
was added to each well by the liquid handling device, left for
10 min and aspirated. This wash cycle was performed three times.
Biotinylated goat anti-human-IgG (Jackson Immunoresearch) was
diluted to 1:5000 and 50 ml aliquots were applied to each well.
After 1 h incubation at room temperature the secondary antibody
solution was removed and wells were washed three times, as
described above. Horseradish peroxidase (HRP) conjugated to
NeutrAvidin (Sigma) was diluted to 1:4000 and applied to the wells
(50 ml/well) for 1 h at room temperature. Wells were washed as
before. Finally, chemiluminescent Femto substrate (Pierce) diluted
1:5 (i.e., 0.5 ml solution A, 0.5 ml solution B with 4 ml PBS) was
applied to the wells at 50 ml/well and plates were read using an
Envision plate reader after 2.5 min incubation at 22uC.
ELISA measurements were made with both pooled and
individual serum samples. Serum pools were made by combining
patients sera from; stage 1 T. b. gambiense patients (n = 10), stage 2
T. b. gambiense patients (n = 40) and matched uninfected patients
Table 1. Trypanosome proteins selectively recognised by T. b. gambiense infection IgG.
MASCOT score Protein description Protein/Gene ID Mass
Peptides
matched
2796 75 kDa Invariant Surface Glycoprotein (ISG) Uniref100_Q26769 58591 100
1456 Gene related to Expression site-associated gene (GRESAG) 4 Tb927.7.7530 137920 67
1152 Expression site-associated gene (ESAG) 7 Tb427 telo10 v1 145 38433 31
1098 65 kDa ISG Uniref100_Q26712 48192 39
582 64 kDa ISG Tb927.5.1410 46867 23
510 Polyubiquitin Tb11.01.1680 76556 10
368 Hypothetical protein 3020 Tb927.6.3020 32198 8
256 ESAG6 Uniref100_Q8WPU1 44221 10
235 ESAG2 Tb927.1.4890 53686 7
220 Flagellar calcium-binding protein TB-17 UniRef100_P17882 25477 6
209 Hypothetical protein 0210 Uniref100_Q386P9 51028 3
202 Hypothetical protein 2120 Tb927.7.2120 46341 6
185 Phosphoribosylpyrophosphate synthetase, Tb10.6k15.0970 40452 7
156 ESAG11 Tb927.1.4900 32032 5
140 Hypothetical protein 4180 Tb927.6.4180 16317 2
121 ESAG3 UniRef100_Q8WPR9 42744 5
89 Gp63-3 surface protease homology Uniref100_Q4FKH2 70254 2
82 Hypothetical protein 1300 Tb927.3.1300 46343 2
70 RNA binding protein (RBP29) Tb10.61.3200 41052 5
70 Hypothetical protein 2570 Tb927.7.2570 52912 2
59 Flagellum-adhesion glycoprotein Tb927.8.4060 64947 1
56 Hypothetical protein 4300 Tb11.02.4300 48868 2
56 Hypothetical protein 1910 Tb11.02.1910 36953 2
52 Hypothetical protein 2100 Tb927.5.2100 49921 2
doi:10.1371/journal.pntd.0002087.t001
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(n = 50); and from stage 1 T. b. rhodesiense patients (n = 5), stage 2 T.
b. rhodesiense patients (n = 20) and matched uninfected patients
(n = 25). The pooled sera were diluted to 1:60 in 50% glycerol,
PBS and 1% BSA and stored at 220uC. For ELISA assays, the
1:60 diluted pooled sera were further diluted to 1:1000 in PBS,
0.1% BSA and then serially diluted (doubling dilutions) to
1:32,000. For the individual sera, the 1:60 diluted samples were
further diluted to 1:1000 immediately before use.
Randomisation of sera
Sera were randomised by a member of the University of
Dundee Tissue Bank. Forty T. b. gambiense infected patients sera
and forty T. b. gambiense uninfected patients sera were randomly
selected from the fifty T. b. gambiense infected and fifty uninfected
WHO patient sera. These eighty serum samples were then
randomised and coded.
Prototype lateral flow test
Serum aliquots (5 ml) were diluted with 15 ml PBS and applied
to the sample pad. Chase buffer (80 ml of PBS, 0.05% Tween 20)
was added to the sample pad and the test was allowed to develop
for 30 min. The test line was visually scored and the device was
opened and the sample pads (at top and bottom of nitrocellulose
membrane) were removed to prevent backflow. The lateral flow
tests were photographed and scanned using a densitometer
(CAMAG TLC scanner 3, CAMAG).
Statistics
Bar graphs and scatter plots (x by y) were generated by
Microsoft Excel. Box plots, Receiver Operator Characteristic
(ROC) curves, antigen scatter plots (y axis only) were generated by
SigmaPlot 12. Statistical analysis included Mann-Whitney (Rank
Sum Test) and Dunn’s post-hoc (Analysis of Variance (ANOVA)
Figure 3. ELISA results with pooled human sera. (A) Pooled human sera representing stage 1 T. b. gambiense infections (pool of 10 sera), stage
2 T. b. gambiense infections (pool of 40 sera) and matched uninfected controls (pool of 50 sera) were diluted 1:1000 and used in triplicate on ELISA
plates coated with the rISG75, rISG65-1, rISG65-2, rISG64-1, rISG64-2, rISG64-3 and rGRESAG4a recombinant proteins described in (Figure 2). The mean
ELISA signals6 SEM are plotted against the recombinant protein used in the ELISA. (B) As panel A but using pooled human sera representing stage 1
T. b. rhodesiense infections (pool of 5 sera), stage 2 T. b. rhodesiense infections (pool of 20 sera) and matched uninfected controls (pool of 25 sera).
doi:10.1371/journal.pntd.0002087.g003
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Figure 4. ELISA results using individual T. b. gambiense infection and matched control sera. (A–F) Box plots (generated by Cleveland
method) represent the 25th percentile to the 75th percentile boundaries in the box with the median line within the box, the whiskers indicate the 10th
and 90th percentiles. The box plots show ELISA signals for each recombinant protein ELISA plate: (A) rISG64-1, (B) rISG64-2, (C) rISG64-3, (D) rISG65-1,
(E) rISG65-2 and (F) rISG75) tested against individual sera diluted 1:1000 from stage 1 T. b. gambiense infections (n = 10), stage 2 T. b. gambiense
A Diagnostic Device for African Trypanosomiasis
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on rank) in SigmaPlot 12. Data were tested for normality by
Kolmogorov-Smirnov test and were further processed by Mann-
Whitney or Dunn’s post-hoc tests. The P values were recorded for
Mann-Whitney with ,0.05 set as the cut off for statistical
significance.
Results
Antigen identification
We took a non-biased proteomics approach to identify proteins
that adsorb selectively to pooled infection IgG, and not to pooled
control IgG (Figure 2A). Each serum pool contained four individual
sera of patients clinically defined as having an infection with T. b.
gambiense or as being uninfected. IgG fractions were purified from
the pooled sera by affinity chromatography on protein G and then
immobilised to cyanogen bromide-activated Sepharose beads.
Equal amounts of infection and control IgG-Sepharose were
incubated with equal amounts of T. b. brucei detergent cell lysate.
Proteins that bound to the IgG columns were eluted by low pH,
precipitated with cold ethanol, dissolved in SDS-sample buffer,
reduced, separated by SDS-PAGE and stained with colloidal
Coomassie blue (Figure 2B). More protein was seen in the eluate
from the infection IgG column, consistent with infection-specific
anti-trypanosome immune responses. Equivalent sections were cut
out from the infection and control lanes, as indicated (Figure 2B).
The excised gel pieces underwent in-gel S-alkylation and tryptic
digestion, and the tryptic peptides were analysed by LC-MS/MS.
Mascot software matched the peptide spectra to proteins in the T. b.
brucei predicted protein database and scored the quality of the
identifications. Lists of the proteins retained by infection IgG-
Sepharose and control IgG-Sepharose were compared in each gel
section. Twenty-four proteins with a MASCOT protein score above
50 were found uniquely in the infection IgG eluate and these are
described in (Table 1). Several of the infection-specific proteins were
defined as ‘hypothetical’, but other hits included known cell surface
proteins, such as: Invariant Surface Glycoprotein (ISG) 75, ISG65,
ISG64, Gene Related to Expression Site Associated Gene
(GRESAG) 4, and the transferrin receptor subunits ESAG 6 and
7. As a starting point, the proteins with high MASCOT scores were
prioritised. The rationale for this selection was that, by using an
excess of trypanosome lysate in the affinity purification step, the
amount of an eluted antigen should reflect, to a first approximation,
the relative amount of antigen-specific immobilised IgG. The latter
should, in turn, correspond to the immune response to that antigen
in infected patients. Using this criterion, the protein antigens
selected for study were ISG75, ESAG7, GRESAG4, ISG65, ISG64
and ESAG6 (Table 1). Next, we looked into the likely ease of protein
expression of these antigens in E. coli. At this stage, we de-selected
ESAG6 and ESAG7 because they form a heterodimer (adding the
complication of dual expression) and because successful (but low
level) protein expression has only been reported in a eukaryotic
baculovirus expression system [47]. On the other hand, E. coli
recombinant expression of domains of ISG75, ISG65 and ISG64
had either been reported in the literature [48] or were known to the
authors (Mark Carrington, unpublished data). Consequently, we
selected all three ISGs for protein expression trials. Finally, we
performed expression trials on the predicted extracellular domain of
GRESAG4, for which there was no literature precedent.
Initial ELISA screens with pooled sera
The selected purified recombinant trypanosome proteins, see
Supporting Information (Figure S1), were used to prepare ELISA
plates, as described in Experimental Procedures, and these were
screened against various pooled human sera. These pools were
derived from the 145 individual serum samples provided by the
WHO Human African Trypanosomiasis specimen bank. The
pooled sera were for stage 1 T. b. gambiense patients (n = 10), stage 2
T. b. gambiense patients (n = 40) and matched uninfected patients
(n = 50); and from stage 1 T. b. rhodesiense patients (n = 5), stage 2 T.
b. rhodesiense patients (n = 20) and matched uninfected patients
(n = 20). The results indicated that both stage 1 and stage 2 T. b.
gambiense infection sera have significant antibody titres against all of
the rISG64 and rISG65 proteins, compared to pooled non-
infection sera (Figure 3A), whereas infection sera titres against
rISG75 and GRESAG4a were much closer to those for the control
sera. The best performing recombinant protein was ISG65-1,
which had the highest infection to control signal. For the T. b.
rhodesiense pooled sera, the signals were generally significantly
lower, with the stage 2 pooled sera giving a significantly higher
signal than the stage 1 pooled sera. There was one exception to
this; the T. b. rhodesiense stage 1 pool had the highest antibody titre
against rISG75 (Figure 3B). However, as will be described later,
the rISG75 result was due to a very high antibody titre in a single
individual. From these results, all the rISG proteins were taken
forward and screened against the individual sera but GRESAG4a
(rG4a) was abandoned at this stage because it had poor infection
versus non-infection discrimination.
ELISA screens with individual sera
Recombinant protein ELISA plates that performed well in the
pooled sera ELISAs were further screened against all of the
individual sera. These antigens included three rISG64 proteins,
two rISG65 proteins and one rISG75 protein. In this case, a total
of 163 individual serum samples (145 from the WHO HAT
specimen bank and 18 from the Institue of Tropical Medicine,
Antwerp) were diluted and applied in triplicate to wells coated
with single recombinant proteins. T. b. gambiense and T. b. rhodesiense
patient sera ELISA results were analysed separately (Figure 4) and
(Figure 5), respectively. The data are shown as box plots for each
different recombinant antigen ELISA plate (Figures 4A and 5A) to
provide a visualisation the range of antibody titres and the heat
maps provide a different view of the same data (Figures 4B and
5B). Both views suggest that rISG65 proteins provide the highest
detection sensitivity whereas the rISG64-1 may provide slightly
greater specificity. The rISG75 protein did not perform as well as
the rISG65 or rISG64 proteins by both criteria and, indeed, only
the stage 2 sera had statistically significant levels of IgG to rISG75-
1 compared to controls (Q=4.616, P=,0.05). Dunn’s post-hoc
tests (not shown) demonstrated that, whereas there are significantly
higher levels of anti-rISG64 and anti-rISG65 IgG antibodies in
both stage 1 and stage 2 sera compared to uninfected controls,
there is no statistically significant difference between the stage 1
and stage 2 groups. In other words, relative immunoreactivity to
rISG64 or rISG65 antigens cannot be used to stage of the disease.
Formal sensitivity (i.e., the proportion of correct positive results)
and specificity (i.e., the proportion of correct negative results)
parameters for each test were calculated by ROC curve analysis
(Figure 4C and 5C) and are collated in (Table 2). The
infections (n = 40) and matched uninfected controls (n = 50). (G) Heat maps of the same data for the individual sera versus the recombinant protein
ELISA plates. (H) Receiver operating characteristics (ROC) plots of the same data. The output statistics for sensitivity and specificity are shown in
(Table 2).
doi:10.1371/journal.pntd.0002087.g004
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Figure 5. ELISA results using individual T. b. rhodesiense infection and matched control sera. (A–F) Box plots (generated by Cleveland
method) represent the 25th percentile to the 75th percentile boundaries in the box with the median line within the box, the whiskers indicate the 10th
and 90th percentiles. The box plots represent the ELISA signals for each recombinant protein ELISA plate: (A) rISG64-1, (B) rISG64-2, (C) rISG64-3, (D)
rISG65-1, (E) rISG65-2 and (F) rISG75) tested against individual sera diluted 1:1000 from stage 1 T. b. rhodesiense infections (n= 5), stage 2 T. b. rhodesiense
infections (n=20) andmatched uninfected controls (n = 20). (G) Heat maps of the same data for the individual sera versus the recombinant protein ELISA
plates. (H) Receiver operating characteristics (ROC) plots of the same data. The output statistics for sensitivity and specificity are shown in (Table 2).
doi:10.1371/journal.pntd.0002087.g005
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recombinant antigens that best discriminated between T. b.
gambiense infected and control patients by ELISA were rISG65-1
and rISG64-1, which had areas under the ROC curve of 0.99 and
0.98 respectively (Figure 4C). The rISG65-1 ELISA antigen had
sensitivity of 96.6% (with a 95% Confidence Interval (CI) of 88.3
to 99.6%) and specificity of 93.2% (95% CI of 83.5 to 98.1%),
whereas sensitivity and specificity of rISG64-1 antigen was 93.2%
(95% CI of 83.5 to 98.1%) and 94.9% (95% CI of 85.9 to 98.9%),
respectively (Table 2).
It was more difficult to find a recombinant protein antigen that
reliably discriminated T. b. rhodesiense infected patient sera from
non-infected sera. The box plots, heat maps (Figure 5A and B) and
Dunn’s post hoc analyses (not shown) all indicate that, whereas the
stage 2 sera show statistically significant immunoreactivity to all
the antigens compared to controls, the immunoreactivities of the
stage 1 sera are not statistically significant. rISG65-2 was the most
sensitive at identifying T. b. rhodesiense infection sera 92% (95%, CI
of 74 to 99%), but at a cost to specificity 85% (95%, CI 62.1 to
97%) (Figure 5C and Table 2). As mentioned above, the pooled
sera ELISA experiments had indicted that stage 1 T. b. rhodesiense
infection sera might have high antibody titres towards rISG75.
However this proved not to be the case and was due to a single
serum sample with a very high anti-rISG75 titre.
Lateral flow prototype development to detect T. b.
gambiense infections
Based on the ROC curve analyses of the performances of the
ELISA plates, we selected rISG65-1 (ROC curve area 0.99 for T.
b.gambiense sera) for development of a lateral flow prototype.
Purified rISG65-1 was supplied to BBInternational (Dundee,
www.bbigold.com) a company that specialises in lateral flow
technology. The lateral flow approach that was utilised is
illustrated in (Figure 6). Thus, rISG65-1 was both immobilised
in a band on a nitrocellulose membrane and coupled to colloidal
gold that was then localised in the conjugate pad. When the sera
and chase buffer are applied to the sample pad, the rISG65-
colloidal gold conjugate is resuspended. The absorbent pad at the
top of the lateral flow device draws the liquid across the
nitrocellulose membrane. During this time, any anti-rISG65
antibody in the serum binds to the rISG65-gold conjugate and
when the antibodies reach the rISG65 test band, one Fab arm of
the IgG binds to the immobilised rISG65 while the other Fab
domain bridges to the rISG65-gold-conjugate. Accumulation of
this specific antibody sandwich generates a visible test line. The
Table 2. Sensitivities and specificities of the recombinant ISG
ELISAs.
Antigen
Infectious
species Sensitivity 95% CI Specificity 95% CI
rISG65-1 T. b.
gambiense
96.6 88.3 to 99.6 93.2 83.5 to 98.1
T. b.
rhodesiense
84 63.9 to 95.5 75 50.9 to 91.3
rISG65-2 T. b.
gambiense
83.1 71 to 91.6 72.9 59.7 to 83.6
T. b.
rhodesiense
92 74 to 99 85 62.1 to 97
rISG64-1 T. b.
gambiense
93.2 83.5 to 98.1 94.9 85.9 to 98.9
T. b.
rhodesiense
84 63.9 to 95.5 75 50.9 to 91.3
rISG64-2 T. b.
gambiense
88.1 77 to 95.1 86.4 75 to 94
T. b.
rhodesiense
92 74 to 99 80 56.3 to 94.3
rISG64-3 T. b.
gambiense
86.4 75 to 94 83.1 71 to 91.6
T. b.
rhodesiense
88 68.8 to 97.5 85 62.1 to 97
rISG75-1 T. b.
gambiense
72.9 59.7 to 83.6 72.9 59.7 to 83.6
T. b.
rhodesiense
72 50.6 to 87.9 75 50.9 to 91.3
doi:10.1371/journal.pntd.0002087.t002
Figure 6. Prototype lateral flow device for detecting antibodies to rISG65-1 protein. Representative results using serum samples from a
matched uninfected patient (left) and a stage 2 T. b. gambiense infected patient (right). The visual scores for these test lines were 0 and 5, respectively,
and the CAMAG densitometry measurements were 24.2 and 597.4, respectively. The inset shows the principle of detection, with patient antibody to
ISG65 forming a bridge between rISG56-1 immobilised on the nitrocellulose strip and the colloidal gold-coupled rISG65-1 picked up from the sample
pad.
doi:10.1371/journal.pntd.0002087.g006
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control line is an internal positive control for the lateral flow test
and does not relate to the infection status of the patient but
indicates successful test flow. The final reading of this test should
be as follows; the appearance of only a control line (upper band)
indicates non-infected sera, whereas, the appearance of two lines, a
control and test line (upper & lower bands) indicates infected sera,
examples are shown in (Figure 6). Absence of a control line (upper
band) indicates an invalid test, irrespective of the appearance of
the test line and the test should be repeated.
Prototype validation
Eighty randomised and coded WHO ‘test’ T. b. gambiense sera,
comprising forty infected and forty non-infected sera were
applied to the lateral flow prototypes. Each serum sample (5 ml)
was diluted with 15 ml of PBS and applied to a lateral flow device
sample pad. Within about 30 s, 80 ml of chase buffer was added
and the test was left for 30 min, at which point a visual score was
recorded. The sample pads were removed to prevent back flow
and the visual scores were decoded (Figure 7). Sensitivity and
specificity were calculated by ROC curve analysis, and for visual
scores a cut off of 2.5 gave 100% sensitivity (95% CI of 91.1 to
100) and 87.5% specificity (95% CI of 73.2 to 95.8%). An
analysis of the test lines was also carried out using a densitometer,
where an arbitrary cut off at 265.6 RU gave 100% sensitivity
(95% CI of 91.2 to 100%) and 92.5% specificity (95% of CI 79.6
to 98.4%) (Table 3) indicating there is potential for separation
between infection and non-infected individual scores. Principally
the end user will interpret the results visually therefore further
optimisation of the test line will be necessary to reduce false
positive results due to non-specific binding. A checklist, Support-
ing Information (Table S2), and flow diagram, Supporting
Information (Figure S2), are provided according to the STAn-
dards for the Reporting of Diagnostic accuracy studies (STARD)
guidelines.
Figure 7. Performance of the prototype lateral flow device in a blinded study with eighty randomised serum samples. (A) Visual
scores of test line density from rISG65-1 prototype lateral flow devices (scored in increments of 1 from 0 to 5, with very faint test line shadows
represented as 0.5) are plotted against the subsequently decoded patient status (stage 1 T. b. gambiense infections (n = 8), stage 2 T. b. gambiense
infections (n = 32) and matched uninfected controls (n = 40). (B) The same test strips were removed from the devices and scanned by CAMAG
densitometer. The data are plotted directly below the results for the visual scores for the same samples. The R2 of a scatter plot was 0.96, showing
very good correlation between visual score and CAMAG reading. (C–E) Box plots of the results for the same serum samples analysed by (C) rISG65-1
ELISA, (D) rISG65-1 lateral flow prototype with visual scoring and (E) rISG65-1 lateral flow prototype with CAMAG scanner scoring.
doi:10.1371/journal.pntd.0002087.g007
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Discussion
The overall goal of this project was to develop an immuno-
diagnostic lateral flow prototype for human African trypanoso-
miasis that might be developed into a field-based device to
replace the CATT screening tool. To do this, we needed to
identify potential diagnostic antigen candidates, investigate
whether they could be adequately expressed and purified and
assess their diagnostic potential with patient sera. We took an
unbiased proteomics approach to identify more than twenty
potential diagnostic protein antigens, several of which were
known cell-surface glycoproteins. This list was filtered pragmat-
ically; first, the proteins with high proteomic MASCOT scores,
generally synonymous with their abundance, were selected
because, by using an excess of trypanosome lysate in the affinity
purification step, the amount of an eluted antigen should reflect
the relative amount of antigen-specific IgG in infection sera. The
latter should, in turn, correspond to the immune response to that
antigen in infected patients. From this list we eliminated ESAG6,
since it is known to form a heterodimer with ESAG7 and is,
therefore, relatively complicated to express [46]. Our attempts to
express parts of the extracellular domain of GRESG4 in E. coli
were not very successful, although we were able to isolate the A-
domain fused to GST. However, this G4a construct and the
ISG75 protein construct did not perform well in the ELISA
studies and were removed from this study. Nevertheless, these
antigens should not be ignored for diagnostic development as
they may simply have been miss-folded in the absence of
endoplasmic reticulum folding and quality control components
[49]. Indeed, recombinant ISG75 has been shown to have
diagnostic potential for T. b. brucei animal infections [47]. Future
expression attempts might include bacterial expression systems
that target recombinant proteins into the periplasmic space [49]
and/or eukaryotic expression systems such as insect cells and
Pichia pastoris.
Our data on the diagnostic potential of ISGs 64, 65 and 75 for
detecting T. b. rhodesiense infections were somewhat hampered by
the small number of sera available for testing. Nevertheless, it is
clear from the ELISA data that IgG antibody responses to these
antigens are lower than in T. b. gambiense infections. Further, the
IgG responses are particularly low in stage 1 T. b. rhodesiense patient
sera. This may be due to the differing nature and speed of
progression of the infections; T. b. rhodesiense infections are usually
acute and progress faster whereas T. b. gambiense infections are
chronic and progress over months or years [50], which could in
turn lead to a greater amount and diversity of antibodies present in
these sera. A previous study also struggled to identify diagnostic
antigens for T. b. rhodesiense infections [51]. A good approach may
be to repeat the procedures described here using immobilised IgG
from T. b. rhodesiense patient sera.
Further research is also required to measure the half-life of
antibodies in patients after they have been treated for HAT, as
persistent antibodies may lead to false positives. It has been
described that antibodies can persist up to 3 years post cure,
however it is not known which class of antibodies persist or which
antigens they recognise [52]. Ideally, a longitudinal study could be
carried out to gain a greater insight into this and how it could
affect the diagnostic potential of any future lateral flow test relying
on antibodies [32]. Lateral flow tests, whilst having limitations,
could potentially be more suitable for use in the field because of
their stability and the fact that they can be used by non-specialists
[53].
In summary, we report here the selection of ISG65-1 as a
potential diagnostic antigen for T. b. gambiense infections and its
performance in both conventional ELISA and prototype lateral
flow device assays looks promising. The performance of the
prototype ISG65 lateral flow device encourages us to further
develop and optimize it, perhaps adding an additional antigen or
antigens to improve sensitivity and specificity, while aiming for a
production cost of ,US$1 per unit.
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